Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 12, 2026Transfusion Medicine and HemotherapyOpen Access

Extended Half-Life Factor Concentrates in Haemophilia Treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

KHKatharina HolsteinUniversity Hospital Schleswig-HolsteinTBTido BajoratClinical Research Center KielRBRafael BeckUniversity Hospital Schleswig-Holstein

Discussion

Loading...

Member takes

Implication

This review summarizes the benefits of extended half-life factor concentrates in haemophilia treatments, showing improved outcomes and reduced treatment burden.

Key Points

  • The review aims to summarize the advancements in extended half-life (EHL) factor concentrates for haemophilia A and B treatment.
  • Reviewed existing literature on EHL and its mechanisms of action including Fc-fusion and PEGylation.
  • Analysed clinical trial data related to EHL factor concentrates and their real-world applications.
  • Evaluated safety aspects of EHL, especially in young children with respect to PEG-related concerns.
  • EHL factor concentrates allow for less frequent infusions and significantly reduce annual bleed rates (ABR).
  • Patients using EHL reported better joint health and higher quality of life than those on standard half-life concentrates.
  • Inhibitor rates in previously treated patients are low, with some evidence suggesting similar or lower rates compared to standard half-life therapies.

Cite This Study

Holstein et al. (2026) studied this question.

synapsesocial.com/papers/69b2579096eeacc4fcec651chttps://doi.org/10.1159/000551421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Use of Extended Half-Life Factor IX in Children with Haemophilia B2025
  2. 2Extended Half‐Life Recombinant Factor VIII Conjugated with Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples2026
  3. 3A revised classification of FVIII concentrates: rationale and novel metrics2026 · 5 citations
  4. 4Experience of tertiary prophylaxis with extended half-life factor prophylaxis in India2024
  5. 5Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa2025